Quote:
Originally Posted by Neil Cuadra
If this correlation pans out in further studies, it could benefit both the patients likely to suffer from GVHD and those who are less likely. In both cases, post transplant treatment could be modified based on the GVHD risk.
Those with a high level of ST2, indicating that GVHD is more likely, might get earlier intervention or higher doses of immunosuppressives, while those with a low ST2 level would be able to take smaller doses and avoid the associated side effects.
|
It sounds promising as do the other articles that make references to markers @ that website. Don't know how hard it is to test for ST2 but sounds reasonable enough that if it had promise BMT clinicians would be all over it. After all how hard could it be to test blood? Encouraging to see them look for markers, lets hope they find one.
Thx for posting!!